Upcoming treatments for morphea

Abstract Morphea (localized scleroderma) is a rare autoimmune connective tissue disease with variable clinical presentations, with an annual incidence of 0.4–2.7 cases per 100,000. Morphea occurs most frequently in children aged 2–14 years, and the disease exhibits a female predominance. Insights in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dan Wenzel, Nazgol‐Sadat Haddadi, Khashayar Afshari, Jillian M. Richmond, Mehdi Rashighi
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	clinical trial localized scleroderma morphea treatment Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/c979b079617a4b38afa6c44a5b637f4c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c979b079617a4b38afa6c44a5b637f4c
record_format	dspace
spelling	oai:doaj.org-article:c979b079617a4b38afa6c44a5b637f4c2021-11-12T19:57:14ZUpcoming treatments for morphea2050-452710.1002/iid3.475https://doaj.org/article/c979b079617a4b38afa6c44a5b637f4c2021-12-01T00:00:00Zhttps://doi.org/10.1002/iid3.475https://doaj.org/toc/2050-4527Abstract Morphea (localized scleroderma) is a rare autoimmune connective tissue disease with variable clinical presentations, with an annual incidence of 0.4–2.7 cases per 100,000. Morphea occurs most frequently in children aged 2–14 years, and the disease exhibits a female predominance. Insights into morphea pathogenesis are often extrapolated from studies of systemic sclerosis due to their similar skin histopathologic features; however, clinically they are two distinct diseases as evidenced by different demographics, clinical features, disease course and prognosis. An interplay between genetic factors, epigenetic modifications, immune and vascular dysfunction, along with environmental hits are considered as the main contributors to morphea pathogenesis. In this review, we describe potential new therapies for morphea based on both preclinical evidence and ongoing clinical trials. We focus on different classes of therapeutics, including antifibrotic, anti‐inflammatory, cellular and gene therapy, and antisenolytic approaches, and how these target different aspects of disease pathogenesis.Dan WenzelNazgol‐Sadat HaddadiKhashayar AfshariJillian M. RichmondMehdi RashighiWileyarticleclinical triallocalized sclerodermamorpheatreatmentImmunologic diseases. AllergyRC581-607ENImmunity, Inflammation and Disease, Vol 9, Iss 4, Pp 1101-1145 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	clinical trial localized scleroderma morphea treatment Immunologic diseases. Allergy RC581-607
spellingShingle	clinical trial localized scleroderma morphea treatment Immunologic diseases. Allergy RC581-607 Dan Wenzel Nazgol‐Sadat Haddadi Khashayar Afshari Jillian M. Richmond Mehdi Rashighi Upcoming treatments for morphea
description	Abstract Morphea (localized scleroderma) is a rare autoimmune connective tissue disease with variable clinical presentations, with an annual incidence of 0.4–2.7 cases per 100,000. Morphea occurs most frequently in children aged 2–14 years, and the disease exhibits a female predominance. Insights into morphea pathogenesis are often extrapolated from studies of systemic sclerosis due to their similar skin histopathologic features; however, clinically they are two distinct diseases as evidenced by different demographics, clinical features, disease course and prognosis. An interplay between genetic factors, epigenetic modifications, immune and vascular dysfunction, along with environmental hits are considered as the main contributors to morphea pathogenesis. In this review, we describe potential new therapies for morphea based on both preclinical evidence and ongoing clinical trials. We focus on different classes of therapeutics, including antifibrotic, anti‐inflammatory, cellular and gene therapy, and antisenolytic approaches, and how these target different aspects of disease pathogenesis.
format	article
author	Dan Wenzel Nazgol‐Sadat Haddadi Khashayar Afshari Jillian M. Richmond Mehdi Rashighi
author_facet	Dan Wenzel Nazgol‐Sadat Haddadi Khashayar Afshari Jillian M. Richmond Mehdi Rashighi
author_sort	Dan Wenzel
title	Upcoming treatments for morphea
title_short	Upcoming treatments for morphea
title_full	Upcoming treatments for morphea
title_fullStr	Upcoming treatments for morphea
title_full_unstemmed	Upcoming treatments for morphea
title_sort	upcoming treatments for morphea
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/c979b079617a4b38afa6c44a5b637f4c
work_keys_str_mv	AT danwenzel upcomingtreatmentsformorphea AT nazgolsadathaddadi upcomingtreatmentsformorphea AT khashayarafshari upcomingtreatmentsformorphea AT jillianmrichmond upcomingtreatmentsformorphea AT mehdirashighi upcomingtreatmentsformorphea
_version_	1718430341465636864

Upcoming treatments for morphea

Ejemplares similares